Australia's most trusted
source of pharma news
Wednesday, 04 February 2026
Posted 3 February 2026 AM
With Afqlir now listed on the PBS, Sandoz plans to launch a national survey to ensure uptake of the medicine across Australia.
Afqlir provides the first PBS listed biosimilar alternative to Bayer’s blockbuster anti-VEGF drug Eylea for Australians living with various neovascular-related conditions, such as neovascular (wet) age-related macular degeneration (nAMD) – the leading cause of vision loss in older adults in Australia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.